TGMC Earns Gold Plus Awards from The American Heart and Stroke Association

Terrebonne General Medical Center (TGMC) has received the American Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold Quality Achievement Award with Target: StrokeSM Honor Roll Elite, Target: Type 2 Diabetes Honor Roll, and Mission: Lifeline- STEMI Receiving Center. TGMC was recognized with these awards because of their commitment and success ensuring that patients receive the most appropriate treatment according to nationally recognized, research-based guidelines based on the latest scientific evidence.  Specific criteria and standards of performance for quick and appropriate treatment through emergency procedures to re-establish blood flow to blocked arteries in heart attack patients coming into the hospital directly or by transfer from another facility were also included in the award criteria.

Through a long-standing partnership with Cardiovascular Institute of the South, TGMC treats over 3,200 cardiac patients annually.

“I am extremely proud of our physicians and staff for their continued dedication to our cardiac patients as the AHA Gold Plus Awards is a testament to TGMC’s commitment for providing the highest quality care and offering the most advanced treatment options in our state that are proven to result in better outcomes,” said Phyllis Peoples, TGMC president and CEO.

The American Heart Association’s Mission: Lifeline program’s goal is to reduce system barriers to prompt treatment for heart attacks, beginning with the 9-1-1 call, to EMS transport and continuing through hospital treatment and discharge. The initiative provides tools, training and other resources to support heart attack care following protocols from the most recent evidence-based treatment guidelines.

To qualify for the Target: Stroke Honor Roll Elite, hospitals must meet quality measures developed to reduce the time between the patient’s arrival at the hospital and treatment with the clot-buster tissue plasminogen activator, or tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke. If given intravenously in the first three hours after the start of stroke symptoms, tPA has been shown to significantly reduce the effects of stroke and lessen the chance of permanent disability. TGMC earned this award by meeting specific quality achievement measures for the diagnosis and treatment of stroke patients at a set level for a designated period.

To qualify for Target: Type 2 Diabetes Honor Roll, hospitals must meet quality measures developed with more than 90 % of compliance for 12 consecutive months for the “Overall Diabetes Cardiovascular Initiative Composite Score.” TGMC also earned this award by achieving specific measures for the diagnosis and treatment of type 2 Diabetes patients at a set level for a designated period.